Esperion Therapeutics, Inc. Share Price & Technical Analysis
ESPR · $3.12 (-0.32%)
Healthcare / Drug Manufacturers - Specialty & Generic
$3.12
-0.32%
Esperion Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C) in the United States. The company's marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary…
Price chart
Seasonality
May has 2 positive and 1 negative years (last 5 years shown)
0% return in May, 3% avg return in past 3 year May month.
-63% return in 2026, 38% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -13% | -3% | -18% | -29% | 0% | – | – | – | – | – | – | – | -63% |
| 25 | -18% | -6% | -22% | -33% | -10% | 11% | 40% | 57% | 23% | 15% | 33% | -5% | 85% |
| 24 | -28% | 14% | 8% | -26% | 10% | 0% | 5% | -22% | -11% | 18% | 33% | -21% | -21% |
| 23 | 2% | -2% | -74% | -19% | 8% | 8% | 14% | -6% | -37% | -20% | 63% | 114% | 50% |
| 22 | -16% | -5% | 15% | 21% | 0% | 12% | -8% | 29% | -12% | 19% | -16% | -7% | 33% |
Monthly return % by calendar month · historical pattern, not a forecast
Neutral · Strong · Strong
Esperion Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C) in the United States. The company's marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia cardiovascular disease who require additional lowering of LDL-C. Its products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. It has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was formerly known as HDL Therapeutics, Inc. and changed its name to Esperion Therapeutics, Inc. in May 2008. The company was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$808.34M
P/E ratio
—
52W high
$4.18
52W low
$0.79
Volume
66,48,773
Beta
0.91
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Esperion Therapeutics, Inc. share price today?
- Esperion Therapeutics, Inc. (ESPR) last traded around $3.12 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does ESPR have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for ESPR. Download the app for real-time alerts.
- How can I analyze Esperion Therapeutics, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.